ChemotherapyPhase 3 trialInvestigational
Temozolomide
How it works
Temozolomide is a small molecule that interferes with DNA replication, causing cancer cells to die. It also triggers apoptosis in cancer cells.
Cancer types
Pancreatic Cancer— All patients
Efficacy
Studies show that temozolomide can improve overall survival in patients with pancreatic cancer, with a median survival of approximately 6.3 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Natural Killer Cell Therapy and Temozolomide for Stage IV Melanoma | Melanoma | phase-1 | — | Source → |
| New Cancer Treatments Being Developed to Replace Current Therapies | Melanoma | review | — | Source → |
| Temozolomide and M1774 Cancer Trial | Colorectal Cancer | phase-1 | — | Source → |
| New Delivery Method for Cancer Treatment | Melanoma | lab-study | — | Source → |
| Woman with advanced melanoma responds well to single chemotherapy drug | Melanoma | observational | — | Source → |
| Combining Traditional Chinese Medicine with Temozolomide May Help Treat Melanoma | Melanoma | lab-study | — | Source → |
| Temozolomide May Help Treat Advanced Pancreatic Tumors | Pancreatic Cancer | meta-analysis | The pooled objective response rate was 41.2%. | Source → |
| Combining Apatinib and Temozolomide in Advanced Melanoma | Melanoma | phase-2 | The objective response rate was 17.2%, and the disease control rate was 82.8%. | Source → |
| Rare Skin Reaction to Cancer Drug Temozolomide | Melanoma | observational | — | Source → |
| Sequential Treatment for Pancreatic Neuroendocrine Tumors | Pancreatic Cancer | observational | The objective response rate with second-line treatment was higher in one group (21.1%) than in the other (5.3%). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.